Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation

Heart Rhythm. 2013 Apr;10(4):483-9. doi: 10.1016/j.hrthm.2012.12.011. Epub 2012 Dec 11.

Abstract

Background: It is not clear whether dabigatran is as safe and effective as uninterrupted anticoagulation with warfarin during radiofrequency catheter ablation (RFA) of atrial fibrillation (AF).

Objective: To compare the safety and efficacy of dabigatran by using a novel administration protocol and uninterrupted anticoagulation with warfarin for periprocedural anticoagulation in patients undergoing RFA of AF.

Methods: In this case-control analysis, 763 consecutive patients (mean age 61±10 years) underwent RFA of AF using dabigatran (N = 191) or uninterrupted warfarin (N = 572) for periprocedural anticoagulation. In all patients, anticoagulation was started≥4 weeks before RFA. Dabigatran was held after the morning dose on the day before the procedure and resumed 4 hours after vascular hemostasis was achieved.

Results: A transesophageal echocardiogram performed in all patients receiving dabigatran did not demonstrate an intracardiac thrombus. There were no thromboembolic complications in either group. The prevalence of major (4 of 191, 2.1%) and minor (5 of 191, 2.6%) bleeding complications in the dabigatran group were similar to those in the warfarin group (12 of 572, 2.1%; P = 1.0 and 19 of 572, 3.3%; P = .8, respectively). Pericardial tamponade occurred in 2 of 191 (1%) patients in the dabigatran group and in 7 of 572 (1.2%) patients in the warfarin group (P = 1.0). All patients who had a pericardial tamponade, including 2 in the dabigatran group, had uneventful recovery after perdicardiocentesis. On multivariate analysis, international normalized ratio (odds ratio [OR] 4.0; 95% confidence interval [CI] 1.1-15.0; P = .04), clopidogrel use (OR 4.2; 95% CI 1.5-12.3; P = .01), and CHA2DS2-VASc score (OR 1.4; 95% CI 1.1-1.8; P = .01) were the independent risk factors of bleeding complications only in the warfarin group.

Conclusions: When held for approximately 24 hours before the procedure and resumed 4 hours after vascular hemostasis, dabigatran appears to be as safe and effective as uninterrupted warfarin for periprocedural anticoagulation in patients undergoing RFA of AF.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Anticoagulants / therapeutic use
  • Atrial Fibrillation / diagnosis
  • Atrial Fibrillation / drug therapy*
  • Atrial Fibrillation / surgery*
  • Benzimidazoles / adverse effects
  • Benzimidazoles / therapeutic use*
  • Case-Control Studies
  • Catheter Ablation / adverse effects
  • Catheter Ablation / methods*
  • Dabigatran
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Echocardiography, Transesophageal / methods
  • Electrocardiography / methods
  • Female
  • Follow-Up Studies
  • Humans
  • Logistic Models
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Postoperative Care
  • Predictive Value of Tests
  • Preoperative Care
  • Reference Values
  • Risk Assessment
  • Severity of Illness Index
  • Thromboembolism / prevention & control
  • Treatment Outcome
  • Warfarin / adverse effects
  • Warfarin / therapeutic use*
  • beta-Alanine / adverse effects
  • beta-Alanine / analogs & derivatives*
  • beta-Alanine / therapeutic use

Substances

  • Anticoagulants
  • Benzimidazoles
  • beta-Alanine
  • Warfarin
  • Dabigatran